Thank you, and good afternoon, everyone.
quarter conference year call. fourth and financial our update corporate to and XXXX full results Welcome
MindMed's annual The Commission. is the filed Investors of today available release year in and press reporting XXXX, Securities the & our ended December with Media will XX-K the on Form report financial XX, results website, for our be section Exchange and
President. Halperin Chief Schond Executive Joining CFO; our and our is Karlin, Greenway, Medical me Wernli, Dr. Miri today Dan Dr. Officer; our
today's be safety, are without and the Form made report filings of During will plans, limitations, prospects. statements statements projections, SEC, regulatory most the progress partnerships recent with annual including, we forward-looking statements, expectations, These financial are call, making clinical our in candidates, about efficacy XX-K. on our including that subject described the future and risks and to potential, product and various
on made XXXX. You any if undue place statements, such statements, change. reliance are management's X, March forward-looking today, even views are not cautioned MindMed to of update these which obligation to disclaims as
or or in generalized disorder, from dose IIb trial IIa low deficit Phase anxiety our of half cash attention transformational into Phase objective pleased And trial as milestones. on value-driving and our and over readouts and from the financial progress the of propelled the expect corporate XXXX, of with well that year, repeated hyperactivity are This treatment positioned for data We are to position business extremely multiple past disorder proof-of-concept well our MM-XXX our of first key we with MM-XXX year. the we our growth strong forward ADHD. as runway execute to reach GAD,
efficacy data in and initiate autism our clinical in to of expect in the model trial first on the of MM-XXX XXXX first to we of year. MM-XXX half Additionally, later present spectrum disorder a preclinical
the take and reflect a dive we to the have completed updates, like would on further extraordinary moment we Before financial evolution at over I to into that year. MindMed our R&D past
attract industry management individuals CFO; deep of and Schond Commercial our VP to have as pharmaceutical Greenway, high-caliber Bridget with Silva join our in our able Rob Lilienthal Francois VP Dr. as the Global Chief experience Clinical; We our Dr. of been Officer; Regulatory team, Walton such our as as to Affairs.
significant we the changes, also pipeline, Suzanne address personnel addition with strengthen Bruhn deliver have focusing have late We Dr. Crystal where of on medical including options made programs streamlined also best Roger changes Directors, have unmet of the treatment chance major our needs. think the Board Dr. our we to year. and to last our Besides to we resources novel
interest MindMed important long-term that that the a mission, represents add executives steadfastly the is shareholders committed we members to and of our Board our remain to the patients every and course It turn, at pursuing of seek to of help.
for over delivering We will by and adherence tirelessly most dedication and and demonstrated brain living amazed mission, the thoughtfulness the our work committed with remain approach of the our that scientific we our and and health the and our to I execution be I stand believe life-changing employees of toward Our patients conviction of advancing by new and in treatment organizations the course I unmatched the disorders. many to efficiency our as of am organization our talented, year, our progress, continued mission. deeply options one nimble industry. to of coming the team, efficient our confident approach continue have the
but disorder developing D-tartrate form often is lifetime, GAD ADHD. health has treatment persistent their on U.S. there excessive we which GAD I several include approximately updates Symptoms treatment proprietary that will programs, past worry, very anxiety GAD in and little other lead on and R&D an functioning. our are affects social, for a now been decades. the the debilitating can to optimized of of MM-XXX over focused our starting innovation with significant lead MM-XXX. of in is turn X% impairment mental the occupational and program, of lysergide of GAD pharmaceutically adults that to
measured top up to to or The The of XXX study participants trial effects selection clinical its In for this as this and later development for of we GAD receive single GAD. are MM-XXX functional administration in active single XX up the who in our total a initiated August results reduction with The is MM-XXX Enrollment of our its dose Phase of the sites, expected MM-XXX endpoint patient strategy trial dosing. and placebo. post with XXX scientific across primary the for currently IIb primary MM-XXX to will XXXX, treatment at anxiety enroll deepen year. this of administration to plans X the dosing a trial symptoms weeks as in X XX way objective mechanisms under of weeks well results will action. a understanding of arms, of and micrograms after line guide underlying is determine of
is for to later report for conducted We in top data trial and Phase our are in is University repeated also adult year. also IIa designed Phase patients line ADHD The in expect utility this evaluating doses and being Hospital IIa Basel the ADHD. Maastricht evaluate trial ADHD sub-perceptual Netherlands of in to MM-XXX of the therapeutic collaboration University and with with in MM-XXX Switzerland
receive serotonin endpoint models of for dose the of agonism lysergide weekly weeks. effects for been recurrent the strategy, in The broader clinical is mean assessed to a change XX the effects this repeat ADHD serotonin harness X as this primary to modern as first a expects development by symptoms administration after a in study forward agonism. MM-XXX The trial from baseline MM-XXX proof-of-concept part of outside has innovative XX-microgram neuropharmacological twice who both of forward seeks and session-based this of administration the trial our to look weeks X of placebo AISRS comprehensive setting. treatment. the study harnesses is which which explore We that driving of perceptual total enroll or administered that Notably, participants will
With respect property pending These XXXX. dosage of intellectual applications. includes patent methods applications among pending XX with XX projected compositions, portfolio formulations U.S. include advances and others, PCT our dates dosing, in treatment, to strategy, applications covering in and beginning expiration our
as protecting owns Additionally, manufacturing property and and and we our currently for intellectual MindMed and are all reminder, a MM-XXX, clinical data portfolio. retains aggressively rights expanding
offer prosecution patent and since in have how XXXX exclusivity toward in opportunities protection. marketing for and beyond, made forward we advancements to and progress product our detail XXXX we we As significant differentiate strategic greater sharing look milestones the strong candidates
atypical a would MM-XXX, a tolerability R-MDMA, is that repetitive preliminarily I are or that to MDMA like turn prosocial autism for and which to has of impart is been Now development in characterized and by is of ASD, the core the MM-XXX no ASD. effects significant of of with or to social synthetic interaction, communication treat therapies to its a disorder core treatment of restricted profile. favorable behavior prevalence, patterns Despite growing approved there symptoms shown symptoms interest. spectrum disorder, and enantiomer
an R-MDMA of believed connectedness synthetic studies suggests S-enantiomer. it R-MDMA of increased a effect, feelings is in and referred diminished demonstrated a and of racemic that to and while because Preclinical of emotional dopaminergic profile is it MDMA could preferable interpersonal connection. the involve resulting empathogenic to to of serotonin an to engagement or of empathogen action MDMA feelings increased reported prosocial compassion. exhibit sociability increase tolerability often that and acute is The secretion prolactin of its mechanism as is molecule activity compared system the
its demonstrate the having to ASD is medications MM-XXX which currently for population. enhance a or rather aim to and used is often social interaction blunting in engagement ability of result Our a off-label sedating effect, than
of our Over that required the in the advancements preclinical XXXX, we course program, clinical key hitting first-in-human MM-XXX enable significant are to made milestones trial.
animal explore to brain progress of model first an the to activity certain preclinical ASD, the of including half models year. data in of important ASD preclinical made in in we report plan of indications, and comprehensive this health MM-XXX MM-XXX Additionally,
enrolling and This evaluate initiated and volunteers PK/PD a are is of molecules. with believe R, of our successful currently and effects We pharmacological that completion accelerate acute racemic to the physiological in through MM-XXX, parallel, understanding as study X development. endocrine University profile Basel advance Hospital later-stage we pharmacokinetics tolerability, our of study research the the in will XXXX, and In clinical collaboration healthy MDMA. S, subjective designed we of comparative into
excited characterize the soon all also approach We is later and opportunities our extremely targeting development efficacy pharmacodynamics pharmacokinetics to continue and of ASD. of signs of in tolerability, are our to explore of we this to trial as core to MM-XXX, generate I in This clinical early as year. symptoms MM-XXX possible to intended support initiate trial Phase
valuable world The that for development efforts, R&D our our organizations accelerating towards novel of into collaborate cycle to of programs. opportunities aim leading treatment position advance and expansion potential the the potential discoveries management from continued an pipeline life with could provide research disorders. health offer around our with on, collaborations us Moving for we've these to insights that emerge brain existing
other at Hospital program, with both numerous lysergide in compounds and global volunteers investigator-initiated our psychedelic associated and in Basel have healthy data We've collaborated research patents University patient and with the and from This completed Liechti and exclusive evaluating rights populations. ongoing Lab data, Switzerland compounds. includes trials to
a informing and in our generated patent collaboration pipeline date. and Our has number been derisking useful to of drug applications development has
advancing progress strong later for of like would the to into view moment opportunity candidates. commercial development, make also of to to stages continue we product our take discuss As I a our
that mechanisms represent of MM-XXX medical commercial have advance reasons to believe We Each need. MM-XXX. to for disorders opportunities there seeks action program significant novel significant many unmet in are and that
paradigm. This lead past of antipsychotics benzodiazepines, session-based are SSRIs, noted safety over the the innovation therapies past the commercial of the and current years. a rate is There's a U.S. of discussing number by not and the of in diagnosed patients GAD adequately start the dosing decade. GAD of multiple who by delivery as in for incidence Europe I'll the in challenges pharmacological prevalence treated the our and with treatment of tolerability targeting over and MM-XXX of available from low The true is classes individuals try GAD the product asset increasing. and remission the also and been absence increase for a SNRIs, several and opportunity such
Europe serotonin potent large market favorable to and its in U.S. patients in and a leads MM-XXX durable tolerability in pharmacological experience session-based available profound well tells more as research particularly agonist, The significant effects. responses treatment for mechanism is have as having exhausted us conducted its of there profile. psychological and who offer is as the we patients demand receptor driven faster, practitioners could options and and the available approach true innovation class that that care intolerable efficacy delivery safety of all of been health more by action the new of years with The a for segment profound have which continue to on anxiety. is This
well repeat research dosing. is MM-XXX as intended and than intervention studies is now approach this believe that ever. us GAD, only that the this the past dose potential recent will to the more This Extensive symptoms disrupt sustained will pharmacological more single anxiety require needed reductions delivered with after well-designed as decade have model, is for model approach people to in be to of over a living highlighted care as to allow current occasional which rapid remember administration. we in generate of It important clinical
embarked socioeconomic such advance to to seeking and a access and MM-XXX. and recognize superior value of all economic a our payers. pre-commercialization a We potential is with health clinical market external key why clinical of delivery outcomes develop revolutionary the in GAD of strategy, and proposition the the product convince a burden stakeholders plan one economics data acquired document and priorities This profile challenges of value a for is XXXX to generation in research on commercializing of build robust the
of oncology, psychiatry of have that brain other the autoimmune of or treatments Another key in health many delivery areas, care and including care There to the evolution developed existing new also novel in this innovative in were injectable is which successful disorders. models of year the and require examples priority disorders administration to examine ones. Similar been the of products for new other neurology. fields and are in approaches undertaken the introduction models efforts therapeutic enable
available that activities products. part That said, one strategy, our the only programs leverage driven currently seeks of for We by is anticipate both administration neurobiological of would which harness well-established that that and those broader a used approach our are serotonin system. models to to session-based are neurobiologically are commercialization studying oriented similar psychological that the
progress model our each across of reach candidates. path we forward providing we the commercial program to novel our As product greater pipeline on and these forward look maximize for to clarity paradigms, delivery the
Lastly, moving to update. our digital medicine
of potential strategy development complemented access our medicine is and digital drug to product that Our to a adoption, facilitate suite candidates. programs closely by use have the
activities FDA's Our Each as programs oriented a towards medical devices. definition intersession. digital digital underlying periods, within applications sessions, treatment scope between intrasession, anticipate we which and to refer during are of activities platform separate to clinical consists be program we a some of of medicine components, X session, primary referred the medicine of the as that treatment contains during will which
regulatory is continue points guidance FDA or and our candidates other For plan these that medicine care along we the components patients, believe for applications authorities the submission user-friendly things development most delivery, qualify for for to to that ultimate platform approval. engaging develop with to our pathway as we adopt. payers medical receive to of devices, clearance to of and regulatory The make our frictional providers and easiest goal overcome digital product potential
will our CFO, Greenway, turn call Schond? discuss to over our results. I financial to Schond now the
